Health News

The transfer into clinical development of a patient-specific vaccine represents a milestone for Bayer Innovation GmbH. Following approval of the Phase I study by the FDA (Food & Drug Administration) in the United States, the vaccine is now being tested in human subjects. This is the first time that proteins obtained from tobacco plants using magnICON® technology undergo clinical testing…

Read more

Filed under: Pharmacy News
Tags: Drug, Pharmacy, Protein

Related posts

• ZyStor Therapeutics, Inc. Cleared To Begin Clinical Trial For Targeted Protein Therapeutic For The Treatment Of Pompe Disease (0)
  ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, [...]
  
  
• Zyngenia completes $15M Series A financing extension from NEA (0)
  Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, [...]
  
  
• What Protein And Where It Is Located Are Important For Drug Design (0)
  Drugs that target a single signaling pathway that drives tumor development and/or progression have been developed successfully to treat a few forms of cancer. However, in many cases drugs designed using this approach have not worked. Dario Altieri and colleagues, at the University of Massachusetts Medical School, Worcester, have now addressed this issue by using [...]
  
  
• Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC (0)
  Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as [...]
  
  
• USPTO issues patent to Lixte’s lead compounds for treatment of neurological diseases (0)
  Lixte Biotechnology Holdings announces that the United States Patent and Trademark Office awarded a patent for the use of lead compounds from each of two different types of drugs, protein phosphatase inhibitors and histone deacetylase inhibitors, for the potential prevention and treatment of neurodegenerative diseases. Read more [tags] Pharmacy News [/tags]